ALK4290 (dihydrochloride)
ALK4290 dihydrochloride (AKST4290 dihydrochlorid) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3].
Product Specifications
CAS Number
1372127-19-9
Product Name Alternative
AKST4290 (dihydrochloride)
UNSPSC
12352005
Target
CCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/alk4290-dihydrochloride.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC(NC([C@@H](CC2)N(C3CCN(CC4=CC=C(Cl)C(C)=C4)CC3)C2=O)=O)=NC(C)=C1)N(C)C.[H]Cl.[H]Cl
Molecular Formula
C27H36Cl3N5O3
Molecular Weight
584.97
References & Citations
[1]Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila) . May-Jun 2020; 9 (3) :250-259.|[2]NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AP52999PU-N 400 µL
Osteopontin (SPP1) (N-term) Rabbit Polyclonal Antibody
Sign In for Pricing
View Details 
